OTC Monograph Readiness: Evidence, Pathways, and Handoffs

An OTC Monograph readiness assessment should answer a specific question: what evidence supports the proposed US marketing pathway for this particular product, and what remains unresolved? Start with an identified product configuration, its intended uses, and the authorities being relied on. End with a responsible human assessment and a documented handoff—not a percentage presented as permission to market.

The statutory fee definitions describe an OTC monograph drug as a nonprescription drug without an approved new drug application that is governed by section 505G. FDA's explanatory material describes a monograph as establishing conditions such as active ingredients, indications, doses, routes, labeling, and testing. Those descriptions provide orientation; they do not establish that a proposed product satisfies the relevant conditions.

This guide addresses the product-market evidence file, order status, OMUFA questions, contradictions, and responsibilities. It does not replace a product-specific regulatory assessment or the existing production guide. For manufacturing depth, use the public overview of the OTC Topical Drug Manufacturing Guide. Keep the pathway decision and production-quality decision connected, but separately documented.

FDA's drug-or-cosmetic explanation says that classification depends on intended use. It describes cosmetic purposes including cleansing, beautifying, promoting attractiveness, and altering appearance. It describes drug purposes including diagnosing, curing, mitigating, treating, or preventing disease, and affecting the body's structure or function. This is FDA explanatory information about classification, not a determination for your formulation.

The same FDA page explains that a product can have both cosmetic and drug intended uses. Its examples include antidandruff shampoo and moisturizers or makeup marketed with sun-protection claims; it states that products meeting both definitions must comply with both sets of requirements. Do not turn that explanation into a current cosmetic manufacturing-law checklist. This assessment uses the page only for its classification explanation.

As site practice, assemble the intended-use evidence before searching for a matching category. Capture the proposed carton, immediate-container text, website, marketplace listing, sales presentation, instructions, and any other channel the assessment team considers relevant. Record the exact wording and version rather than summarizing everything as skin care or personal care. The purpose is to expose differences for human review, not to claim that this inventory is an exhaustive legal test.

• Identify the proposed user, intended benefit, body site, route, directions, and presentation in one product snapshot.
• Distinguish wording actually proposed for publication from abandoned drafts and competitor examples.
• Ask the regulatory owner to document whether the intended uses indicate a drug, cosmetic, both, or an unresolved classification question.
• If the team changes claims to resolve a concern, update every affected channel and reassess the resulting product—not just the carton.

A category name is a search aid. Formula resemblance is a comparison aid. Neither should be entered as the conclusion of the pathway assessment. A familiar-looking cream can still leave unanswered questions about intended use, ingredient conditions, dosage form, or the authority being relied on.

Section 505G contains several distinct treatments. Subsection (a) begins with nonprescription drugs marketed without an approved application as of March 27, 2020. Its historical predicates matter. A reviewer should identify the applicable provision and supporting history rather than assuming that every modern product concept fits one undifferentiated monograph route.

GRASE means generally recognized as safe and effective. Under (a)(1), the statutory result depends on the specified conditions. These include conformity with the relevant requirements, general nonprescription requirements, and referenced subsections. The dosage-form provisions also refer to use to a material extent and for a material time before March 27, 2020, subject to the stated order-based exceptions. Recording only an active ingredient match leaves that analysis incomplete.

Subsection (a)(3) must not be rewritten as a GRASE finding. It applies only to a drug not described in (a)(1), (2), or (4), and its branches contain their own conformity and historical dosage-form conditions. Its express result is conditional treatment without an approved application and outside the referenced prescription provision. That distinction belongs in the written conclusion, not just in a reviewer's background notes.

The conversion in (b)(8) is also specific: it concerns monographs establishing conditions for drugs described in (a)(1) or (2), representing the most recently promulgated version of those conditions, including specified modifications. It is not a rule that every historical proposal became a final order.

FDA describes OTC Monographs@FDA as a resource for viewing proposed, final, and interim final administrative orders and monographs. The statutory repository provision, 505G(g), separately addresses final and interim final orders in effect and proposed or developing orders. A search result therefore needs interpretation; its presence in the portal is not an effective-date conclusion.

Under the ordinary FDA-initiated process in 505G(b)(2), proposal and final issuance are separate steps. The provision also limits when the final order takes effect by reference to the judicial-review request period. For the expedited interim final orders addressed in (b)(4), the effective date is the date specified by the Secretary. Do not assume that final means immediately effective, or that an interim final order is inactive until a later final order appears.

A proposed administrative order is not operative merely because it has been proposed. At the same time, do not discard historical proposed-monograph material simply because its title contains proposed: subsection (a)(3) expressly uses specified historical proposals as predicates. The practical discipline is to identify why a document matters, not to classify its legal effect by a single word in its title.

When an ingredient, use, strength, route, or other condition is not supported by the identified basis, describe the exact mismatch. Avoid two shortcuts: a new ingredient always requires a full NDA, and any requested change can automatically proceed through an OTC monograph order request. Section 505G contains conditions governing requests and filing; a local comparison cannot substitute for FDA action where that action is needed.

Under 505G(b)(5), a requestor can seek an order determining GRASE and related status, or an order addressing a changed condition of use within the provision's terms. FDA determines whether the request is sufficiently complete and formatted for substantive review. For a changed condition involving a drug subject to (a)(3), the statute requires the request to be made in conjunction with a request for a GRASE determination that FDA files under the specified provision.

Subsection (b)(6) adds filing conditions for a nonprescription drug containing an active ingredient not previously incorporated in the drugs specified there. It addresses information supporting a prima facie demonstration of safe nonprescription marketing and use. The stated alternatives concern a verifiable US history, qualifying foreign marketing and monitoring, or other information FDA determines sufficient when it determines the specified history information is unnecessary. This is not permission for the sponsor to select any evidence it prefers.

For requests covered by (b)(6), FDA may file a request containing the specified information. If that information is missing, the statute directs refusal to file and requires nonprescription marketing pursuant to a new drug application as described there. The appropriate handoff is therefore a defined statutory and evidence question, not a promise that a request will be accepted.

Nor should a team label a dosage-form change minor simply to avoid escalation. Section 505G(c)(1) makes its no-new-order mechanism conditional on retained information about safety, effectiveness, absorption or exposure, and conformity with an applicable administrative order. Separately, 505G(f) preserves the ability to seek or maintain approval under the referenced section 355 application provisions. Here, that is a pointer only—not an explanation of the full application rules.

• Write the unsupported condition in product-specific language and identify the authority searched.
• Separate missing evidence of conformity from an actual difference in the proposed product.
• Ask regulatory to identify the available next step and any necessary FDA interaction.
• Do not estimate application science, cost, speed, or exclusivity from this readiness worksheet.

A useful evidence folder lets a second reviewer reproduce the reasoning without reconstructing months of email. Organize it around questions, not departments. A folder full of source documents is not enough if nobody has linked those documents to the product version under review. Conversely, a polished conclusion is weak if its supporting records cannot be found.

Use three documentary states with written definitions: complete, unresolved, and conflicting. Complete means that the defined evidence item is present, traceable, and adequate for its stated documentary purpose. Unresolved means that information or interpretation is missing. Conflicting means that two records make incompatible assertions. None of these labels, by itself, means legally eligible or approved for batch release.

Keep evidence and interpretation distinguishable. For example, a retained manufacturer declaration is evidence that the manufacturer made a statement; it is not automatically proof that the statement resolves the regulatory question. Record who evaluated it, what corroboration was used, and which limitations remain. Avoid replacing a contradictory record with a corrected copy without preserving the disposition of the original discrepancy.

FDA describes OMUFA as its OTC Monograph drug user fee program, with industry-paid fees supporting regulatory activities related to these drugs. That program description is FDA information. The operative distinctions for the assessment come from the statutory definitions and fee provisions. Keep the program, facility, and request concepts separate.

An OTC monograph order request, or OMOR, is defined as a request submitted under 505G(b)(5). Facility fees concern persons owning qualifying facilities during the statutory applicable period; request fees concern persons submitting OMORs, subject to the statutory provisions. A facility review and a request review are therefore different work items. Do not use a single fee paid checkbox to represent both.

Establish the facility facts before assigning a category

The facility definition addresses foreign or domestic entities under one management at one geographic location or address engaged in manufacturing or processing finished dosage forms. It includes qualifying finished-dosage-form manufacturing under contract. It excludes an entity whose only manufacturing or processing activities are one or more of the specified activities: producing clinical research supplies, testing, or adding outer multipack packaging when each enclosed monograph drug is already in final packaged form.

The only-activities qualification matters. A site that tests and also manufactures finished dosage forms cannot establish the exclusion merely by pointing to its testing work. The statute also contains rules for nearby buildings and multiple management. As site practice, document the operational and management facts before deciding how many facilities the analysis concerns; do not assume that one postal address settles the question.

Keep the CMO definition separate from its fee treatment

The statutory CMO facility definition turns on sales relationships: neither the facility owner nor any affiliate of the owner or facility sells the produced OTC monograph drug directly to US wholesalers, retailers, or consumers. Calling a business a contract manufacturer does not answer that test. Separately, the fee provision gives qualifying CMO facilities reduced fee treatment. Have the business owner confirm the sales facts before finance applies that treatment.

The cessation exception combines cessation of all OTC-monograph-drug activities before the applicable statutory cutoff with an updated establishment registration reflecting the change. A closed production line alone does not establish both elements. For OMORs, the safety-labeling fee exception depends on an FDA finding that the request seeks the specified additions or strengthening of contraindications, warnings, precautions, misuse or abuse risk statements, or safe-use dosage and administration instructions; the provision also identifies the person named as requestor in the order.

Keep finance's conclusion in its own record, supported by the facility facts, applicable-period assessment, and any request-specific finding. Payment evidence should not be used as a substitute for the pathway comparison or the quality unit's production-record review. Finance should receive unresolved business facts, not be asked to settle ingredient eligibility.

A pathway assessment should identify adjacent verification work without pretending to perform it. Section 505G(k)(1) states that, except as provided there, section 505G does not supersede general nonprescription-drug regulations. That is a reason to avoid the shorthand the order is all we need—not a basis for inventing a universal checklist from regulations that have not been assessed.

• Drug Facts: assign a separate applicability and current-text verification using the official 21 CFR 201.66 text and the product's relevant authorities. Return the source, scope, reviewer, and open questions.
• Tamper-evident packaging: assign a separate applicability and current-text verification using the official 21 CFR 211.132 text. Do not infer a universal packaging obligation from this task's presence in the folder.
• Establishment registration and drug listing: assign a separate verification using the official Part 207 text. Identify the entities and activities being assessed rather than treating a registration screenshot as a pathway determination.

The quality control unit has a distinct regulatory role. Under 21 CFR 211.22, it has responsibility and authority to approve or reject the specified materials and drug products, including products manufactured, processed, packed, or held under contract, and authority to review production records. Under 211.192, production and control records, including packaging and labeling records, must be reviewed and approved by the quality control unit before batch release or distribution.

For this site's responsibility model, regulatory owns the reasoned product-pathway assessment, with business, technical, and legal input as appropriate. The quality control unit performs its applicable quality responsibilities; it should not be assigned the entire regulatory analysis simply because it reviews batches. Use the shared Drug CGMP Quality Review section for that production-quality handoff rather than recreating a manufacturing chapter here.

The following exercise is entirely fictional. Harbor Field Products is evaluating a proposed US topical called Meadow Rub. No actual product, FDA order, or regulatory determination is represented. The team has defined twelve documentary items for an initial assessment. Its purpose is to expose unanswered questions before making a market-pathway decision, not to calculate a compliance score.

The draft carton describes moisturizing dry skin. A retained product brief explicitly states that no pain-relief claim is proposed, while the current proposed web page claims temporary relief of minor aches. The team captures this contradiction about the proposed claims, not a supposed incompatibility between cosmetic and drug intended uses. Its retained master-formula snapshot is version F4, while a contractor's product specification references F5. The example deliberately does not identify an eligible ingredient, concentration, or order: those are questions the fictional team has not resolved.

The accounting is checkable: 7 complete + 3 unresolved + 2 conflicting = 12 items. Documentary completion is 7 ÷ 12 × 100 = 58.333…%, or 58.3% rounded to one decimal place. Five items remain open. That proportion describes the team's defined evidence inventory only. It does not mean 58.3% eligible, 58.3% safe, or ready for any batch decision.

Notice why E02 can be complete while E11 is conflicting: the inventory captured the product brief denying a proposed pain-relief claim and the current proposed web page containing that claim, but the contradictory records have not been reconciled. Cosmetic and drug intended uses can coexist; their coexistence is not the contradiction. Likewise, retaining F4 completes the snapshot task without establishing that F4 is the version the contractor intends to make. The team must not count a document's presence as the resolution of every question associated with it.

Suppose the contractor confirms that F5 was an obsolete reference, but the signed corrected specification has not arrived. E12 moves from conflicting to unresolved. The revised accounting is 7 complete + 4 unresolved + 1 conflicting = 12; completion remains 58.3%. This is useful progress in understanding the problem, but it has not completed the evidence item.

The next handoff is specific: the commercial owner reconciles intended-use wording, the contractor supplies the controlled specification, regulatory resolves the pathway and dosage-form questions, and the assigned specialists return their separate verifications. Finance may use the completed business map for its work without treating that progress as a product-eligibility conclusion. The assessment remains open until the responsible reviewers address the substantive questions.

A contradiction deserves a disposition, not just a new attachment. State what disagrees, which product or source versions are affected, who can establish the facts, and which decisions depend on the answer. Where the disagreement concerns interpretation rather than missing facts, route it to the responsible regulatory reviewer instead of repeatedly asking operations to provide the same records.

Separate three situations. Missing evidence means the file cannot yet support an answer. A genuine product mismatch means the proposed configuration differs from the condition being relied on. A source-version conflict means the team may be comparing against the wrong text. These situations can lead to different next actions; calling all three documentation gaps obscures the decision.

• For a claim change, revisit intended use, the condition comparison, and affected public-facing versions.
• For a formula or dosage-form change, identify which previous conclusions depended on the old configuration and request reassessment.
• For an order change, compare the operative text and timing with the source register before updating the conclusion.
• For a site, management, ownership, or sales change, reopen the relevant business-fact and OMUFA review.
• For corrected evidence, preserve the old record's disposition and explain whether the correction changes the conclusion.

Use a bounded change note: previous conclusion, changed fact, affected evidence, responsible reviewer, and resulting action. Do not reopen unrelated work without a reason, but do not leave an old approval attached to a materially different product snapshot. The objective is traceable reasoning across versions, not an ever-growing folder with no clear current position.

The assessment's output should be a short decision record supported by the evidence folder. Identify the product configuration, intended uses, statutory basis considered, relevant source versions and dates, conclusions reached, unresolved questions, and the limits of the review. The following decision table is suggested site practice; it does not create legal categories or authorize marketing.

For contracted work, make the handoff reciprocal. The sponsor's assessment team needs reliable product and facility facts; the contractor needs the identified configuration and approved scope of the work it is being asked to perform. Use Contract Manufacturing Responsibilities to frame responsibility questions, without assuming that a commercial contract reallocates every legal duty.

Use the next review meeting to close decision-relevant gaps, not to polish a completion dashboard. A practical sequence is to stabilize the product facts first, establish the authority second, and then route the distinct assessments to their owners. If those foundations are moving, an apparently complete file can become unreliable quickly.

1. Freeze the product and intended-use snapshot being assessed, including channel-specific claims and formula versions.
2. Name the human owner of the regulatory assessment and identify the technical, business, finance, and quality contributors.
3. Record the precise 505G provision being considered; distinguish GRASE deeming from conditional transitional treatment.
4. Build the official-source register with order status, version relationships, and effective-date analysis.
5. Map the product against relevant conditions, marking missing evidence separately from actual differences.
6. Obtain the distinct Drug Facts, packaging, and registration/listing verification returns without presuming universal applicability.
7. Assess facility and request fee questions separately, using the relevant operational and business facts.
8. Resolve contradictions with preserved dispositions, then issue a bounded decision record and handoff.
9. Set explicit triggers for reassessment when the product, claims, authority, site, ownership, or sales facts change.

Keep detailed manufacturing execution with the existing production owner and the shared GMP Manufacturing Readiness material. This guide's deliverable is narrower: a reproducible account of what supports the proposed pathway, what remains uncertain, and who is responsible for the next decision.